Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis

Trial Details

NCT ID

NCT06543992

Phase

PHASE2

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir

Locations (sample)

• Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

• Patient is an adult female ≥18 and ≤75 years old at the time of informed consent.
• ECGO rating 0-3.
• Histologically or cytologically confirmed breast cancer.
• A new diagnosis of LM, established either by the presence of malignant cells in the CSF or by the combination of characteristic clinical manifestat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.